Maternal plasma plasminogen activator inhibitor-2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy.
OBJECTIVE
In patients with preeclampsia maternal plasma concentration of plasminogen activator inhibitor-2 (PAI-2) is reduced. The objective of the study was to determine if the altered levels of PAI-2 precede the onset of the disease.


METHODS
Plasma PAI-2 was measured at 11-13 weeks of gestation in 119 pregnancies that developed preeclampsia, 85 that developed gestational hypertension and 204 controls.


RESULTS
There were no significant differences in PAI-2 between the preeclampsia, gestational hypertension and controls (1.07 MoM, 1.08 MoM and 0.96 MoM).


CONCLUSIONS
The decrease in plasma PAI-2 observed in preeclampsia does not precede the clinical onset of the disease.
Akolekar
Ranjit
R
Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, Denmark Hill, London, UK.
Cruz
Jader De Jesus
Jde J
Penco
Jose Maria Perez
JM
Zhou
Yi
Y
Nicolaides
Kypros H
KH
D000328:Adult; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D046110:Hypertension, Pregnancy-Induced / Q000097:blood*; D007118:Immunoassay; D008423:Maternal Age; D017396:Plasminogen Activator Inhibitor 2 / Q000097:blood*; D011225:Pre-Eclampsia / Q000097:blood; D011247:Pregnancy; D011261:Pregnancy Trimester, First / Q000097:blood*; D012044:Regression Analysis; D012907:Smoking; D011795:Surveys and Questionnaires
D017396:Plasminogen Activator Inhibitor 2